Related references
Note: Only part of the references are listed.Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Preetesh Jain et al.
BLOOD (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Pratap Neelakantan et al.
BLOOD (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months
Aziz Nazha et al.
HAEMATOLOGICA (2013)
Cancer Drugs in the United States: Justum Pretium-The Just Price
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines
Susan O'Brien et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
David Montani et al.
CIRCULATION (2012)
Nilotinib-Associated Vascular Events
Alfonso Quintas-Cardama et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Clinical cardiac safety profile of nilotinib
Theo D. Kim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
P. D. le Coutre et al.
LEUKEMIA (2012)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R. A. Larson et al.
LEUKEMIA (2012)
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
Elias Jabbour et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
Elias Jabbour et al.
CANCER (2011)
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Considerations in the Management of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
Elias Jabbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
Carlo Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Bending the Cost Curve in Cancer Care
Thomas J. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
Farhad Ravandi et al.
BLOOD (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Elias Jabbour et al.
BLOOD (2009)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Mueller et al.
BLOOD (2009)
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
Nicoletta Testoni et al.
BLOOD (2009)
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2009)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Bleeding Diathesis in Patients With Chronic Myelogenous Leukemia Receiving Dasatinib Therapy
Alfonso Quintas-Cardama et al.
CANCER (2009)
Dasatinib Early Intervention After Cytogenetic or Hematologic Resistance to Imatinib in Patients With Chronic Myeloid Leukemia
Alfonso Quintas-Cardama et al.
CANCER (2009)
Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily Two-Year Follow-Up of a Randomized Phase 2 Study (START-R)
Hagop Kantarjian et al.
CANCER (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Jane F. Apperley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular monitoring in chronic myeloid leukemia - Response to tyrosine kinase inhibitors and prognostic implications
Elias Jabbour et al.
CANCER (2008)
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Hagop Kantarjian et al.
BLOOD (2008)
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jorge Cortes et al.
BLOOD (2007)
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia - No evidence for increased transplant-related toxicity
Elias Jabbour et al.
CANCER (2007)
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
Vivian G. Oehler et al.
BLOOD (2007)
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
Alfonso Quintas-Cardama et al.
LEUKEMIA & LYMPHOMA (2007)
Treatment interruptions and non-adherence with imatinib and associated healthcare costs - A retrospective analysis among managed care patients with chronic myelogenous leukaemia
Theodore Darkow et al.
PHARMACOECONOMICS (2007)
The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
John S. Tokarski et al.
CANCER RESEARCH (2006)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
DA Thomas et al.
BLOOD (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases
C Schoch et al.
LEUKEMIA (2002)
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
BJ Druker et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)